Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The European Innovation Network as a hub for medicines innovation in Europe.
Agricola E, Auriche-Benichou C, Baiao H, Blanquie O, Bodea T, Boráň T, Borg JJ, Cordo' V, Di Marzo M, Dmowski Rugholm L, Ehmann F, Hauksdóttir Hvannberg R, Herold R, Irs A, Jurkovič Mlakar S, Klaus R, Kolehmainen J, Lahorte C, Löbker W, Mäkinen Salmi A, Nuevo Ordoñez Y, O'Dwyer L, Pasmooij AMG, Saeterdal I, Spakova B, Starokozhko V, Ziegele B, Zywiec K. Agricola E, et al. Among authors: di marzo m. Nat Rev Drug Discov. 2024 Jun;23(6):405-406. doi: 10.1038/d41573-024-00039-x. Nat Rev Drug Discov. 2024. PMID: 38467771 No abstract available.
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Tursi A, Mocci G, Scaldaferri F, Napolitano D, Maresca R, Pugliese D, Semprucci G, Savarino E, Cuomo A, Donnarumma L, Bodini G, Pasta A, Maconi G, Cataletti G, Pranzo G, Rodinò S, Sebkova L, Costa F, Ferronato A, Gaiani F, Marzo M, Luppino I, Fabiano G, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Grossi L, Serio M, Scarcelli A, Lorenzetti R, Allegretta L, Chiri S, Grasso G, Antonelli E, Bassotti G, Spagnuolo R, Luzza F, Fanigliulo L, Rocco G, Sacchi C, Zampaletta C, Rocchi C, Bolognini L, Bendia E, Bianco MA, Capone P, Meucci C, Colucci R, Tonti P, Neve V, Della Valle N, Felice C, Pica R, Cocco A, Forti G, Onidi FM, Usai Satta P, Checchin D, Gravina AG, Pellegrino R, Picchio M, Papa A. Tursi A, et al. Among authors: marzo m. Expert Opin Biol Ther. 2024 Jan-Feb;24(1-2):101-109. doi: 10.1080/14712598.2024.2309300. Epub 2024 Jan 25. Expert Opin Biol Ther. 2024. PMID: 38250818
From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies.
Ottaiano A, Ianniello M, Santorsola M, Ruggiero R, Sirica R, Sabbatino F, Perri F, Cascella M, Di Marzo M, Berretta M, Caraglia M, Nasti G, Savarese G. Ottaiano A, et al. Among authors: di marzo m. Biology (Basel). 2023 Aug 29;12(9):1183. doi: 10.3390/biology12091183. Biology (Basel). 2023. PMID: 37759584 Free PMC article. Review.
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG, Parisio L, Variola A, Bossa F, Castiglione F, Marzo M, Piazza N, Aratari A, Savarino EV, Bodini G, Mastronardi M, Micheli F, Mazzuoli S, Ascolani M, Viganò C, Cappello M, Bezzio C, Ciccocioppo R, Scardino G, Sarli E, Pugliese D, Scaldaferri F, Napolitano D, Todeschini A, Geccherle A, Colaci N, Guerra M, Annese M, Testa A, Caiazzo A, Conforti FS, Festa S, Lorenzon G, Marra A, Magiotta A, Baccini F, Amato A, Poshnjari A, Vernero M, Caprioli F, Caviglia GP; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Ribaldone DG, et al. Among authors: marzo m. Dig Liver Dis. 2024 Jan;56(1):77-82. doi: 10.1016/j.dld.2023.07.011. Epub 2023 Jul 19. Dig Liver Dis. 2024. PMID: 37474412
The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine.
Cannella L, Della Monica R, Marretta AL, Iervolino D, Vincenzi B, De Chiara AR, Clemente O, Buonaiuto M, Barretta ML, Di Mauro A, Di Marzo M, Guida M, Badalamenti G, Chiariotti L, Tafuto S. Cannella L, et al. Among authors: di marzo m. Cells. 2023 Jun 15;12(12):1635. doi: 10.3390/cells12121635. Cells. 2023. PMID: 37371106 Free PMC article.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, Zippi M, Napolitano D, Schiavoni E, Pugliese D, Scaldaferri F, Costa F, Marzo M, Serio M, Scarcelli A, Bolognini L, Bendia E, Maconi G, Cannatelli R, Piergallini S, Bodini G, Calabrese F, Ferronato A, Pranzo G, Elisei W, Monterubbianesi R, Faggiani R, Rodinò S, Sebkova L, Grossi L, Gaiani F, Dè Angelis G, Lorenzetti R, Allegretta L, Cazzato AI, Scorza S, Della Valle N, Sacco R, Forti G, Colucci R, Tonti P, Neve V, Rocco G, Sacchi C, Zampaletta C, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Usai Satta P, Picchio M, Papa A. Tursi A, et al. Among authors: marzo m. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1649-1656. doi: 10.1080/14656566.2023.2230126. Epub 2023 Jun 28. Expert Opin Pharmacother. 2023. PMID: 37358928
211 results